We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma
News

SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma

SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma
News

SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SeqWright Inc., a CLIA certified and GLP compliant provider of custom genomic and molecular biology services, announced its entry into the genetically-targeted therapy field through its partnership with PharmaGenoma.

SeqWright will be the exclusive genetic testing provider for PharmaGenoma's HairDX test which evaluates patient responsiveness to the common hair loss treatment, Finasteride.

Finasteride is a commonly prescribed medication for the treatment of Androgenic Alopecia (AGA) or common hair loss. The treatment works by blocking the production of dihydrotesterone (DHT), which is responsible for the loss of hair.

However, due to potential Finasteride side effects, along with variations in responsiveness, many patients are reluctant to begin or continue treatment. In order to overcome this obstacle, HairDX developed a genetic test for Finasteride response which will allow patients to determine if treatment benefits outweigh potential side effects prior to beginning a Finasteride regimen.

"The state of the art research facility at SeqWright was essential to achieving our goals of high quality genetic analysis combined with a turn-around time useful for clinicians," said PharmaGenoma, CEO Andy Goren.
Advertisement